• Home
  • Pharma Sourcing
    • API Sourcing
    • Finished Product
    • Clinical Trial Sourcing
  • Consultancy
    • IDL application
    • CTA application
    • Mergers & Acquisitions
    • Healthcare Investment
    • Medical Tourism >
      • Swiss Revitalization
      • Anti Cancer
      • Detoxification
      • Lipid apheresis
      • Other Tourism
  • About
  • Contact

SwiCino® - Beyond the Promise!

.


China Outbound Investment on Healthcare


China’s outbound foreign direct investment (FDI) in 2016 rose 30% year-on-year to a record high of US$188.8 billion. China’s outbound investment in 2017 is expected to steadily slow down, but it will concentrate on the quality of their investments to achieve stable development and return. With the increasing aging problems in China, Healthcare sector is continued to be the hot spot of investment.  

SwiCino M&A team is dedicated to providing strategic acquisition advice  across a broad range within the healthcare sector, including pharmaceutical manufacturer, pharma distribution and wholesaler, pharmacy, hospitals, dental, medical devices, healthcare IT, beauty Spa and thermal bath hotel in Switzerland. We maintain extensive relationships with strategic buyers and financial sponsors from China, and have assisted several Swiss companies with various forms of financing and M&A initiatives.

Feel free to contact us and SwiCino is beyond the promise!
 

Copyright © 2013-2030 SwiCino Group Ltd · All Rights Reserved
  • Home
  • Pharma Sourcing
    • API Sourcing
    • Finished Product
    • Clinical Trial Sourcing
  • Consultancy
    • IDL application
    • CTA application
    • Mergers & Acquisitions
    • Healthcare Investment
    • Medical Tourism >
      • Swiss Revitalization
      • Anti Cancer
      • Detoxification
      • Lipid apheresis
      • Other Tourism
  • About
  • Contact